Background Maintaining durable immunity following vaccination represents a major challenge, but whether mRNA booster vaccination improves durability is unknown.Methods We measured antibody responses in 55 healthy adults, who received a booster dose of the Pfizer-BioNTech or Moderna vaccine against SARS-CoV-2 and calculated the half-life of the antibody titers. We also measured memory B and T cell responses in a subset of 28 participants. In 13 volunteers who received a second booster vaccine, we measured serum antibody titers and memory B and T cell responses.Results The booster (third immunization) dose at 6 to 10 months increased the half-life of the serum–neutralizing antibody (nAb) titers to 76 days from 56 to 66 days after the primary 2-dose vaccination. A second booster dose (fourth immunization) a year after the primary vaccination further increased the half-life to 88 days. However, despite this modestly improved durability in nAb responses against the ancestral (WA.1) strain, there was a loss of neutralization capacity against the Omicron subvariants BA.2.75.2, BQ.1.1, and XBB.1.5 (48-, 71-, and 66-fold drop in titers, respectively, relative to the WA.1 strain). Although only 45% to 65% of participants demonstrated a detectable nAb titer against the newer variants after the booster (third dose), the response declined to below the detection limit in almost all individuals by 6 months. In contrast, booster vaccination induced antigen-specific memory B and T cells that persisted for at least 6 months.Conclusion The durability of serum antibody responses improves only marginally following booster immunizations with the Pfizer-BioNTech or Moderna mRNA vaccines.
Prabhu S. Arunachalam, Lilin Lai, Hady Samaha, Yupeng Feng, Mengyun Hu, Harold Sai-yin Hui, Bushra Wali, Madison Ellis, Meredith E. Davis-Gardner, Christopher Huerta, Kareem Bechnak, Sarah Bechnak, Matthew Lee, Matthew B. Litvack, Cecilia Losada, Alba Grifoni, Alessandro Sette, Veronika I. Zarnitsyna, Nadine Rouphael, Mehul S. Suthar, Bali Pulendran
Title and authors | Publication | Year |
---|---|---|
A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection
Liu J, Wang L, Kurtesi A, Budylowski P, Potts KG, Menon H, Tan Y, Samaan P, Liu X, Wang Y, Hu Q, Samson R, Qi F, Evseev D, John C, Ellestad KK, Fan Y, Budiman F, Tohan ER, Udayakumar S, Yang J, Marcusson EG, Gingras AC, Mahoney DJ, Ostrowski MA, Martin-Orozco N |
NPJ Vaccines | 2025 |
Rethinking Optimal Immunogens to Face SARS‐CoV‐2 Evolution Through Vaccination
Blanco J, Trinité B, Puig\u2010Barberà J |
Influenza and Other Respiratory Viruses | 2025 |
Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort
Sheehan J, Trauth AJ, Hagensee ME, Ramsay AJ |
Pathogens | 2025 |
Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters
da Silva Antunes R, Fajardo-Rosas V, Yu ED, Gálvez RI, Abawi A, Alexandar Escarrega E, Martínez-Pérez A, Johansson E, Goodwin B, Frazier A, Dan JM, Crotty S, Seumois G, Weiskopf D, Vijayanand P, Sette A |
bioRxiv | 2025 |
Evaluation of COVID-19 Booster Vaccine Effectiveness
Qu B, Zhang D |
Viruses | 2025 |
LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment
Xue Y, Hou X, Zhong Y, Zhang Y, Du S, Kang DD, Wang L, Wang C, Li H, Wang S, Liu Z, Tian M, Guo K, Cao D, Deng B, McComb DW, Purisic E, Dai J, Hamon P, Brown BD, Tsankova NM, Merad M, Irvine DJ, Weiss R, Dong Y |
Nature Communications | 2025 |
Dynamic SARS-CoV-2-specific B-cell and T-cell responses induced in people living with HIV after a full course of inactivated SARS-CoV-2 vaccine
Wang X, Yang X, Zhang X, Yan H, Jin J, Ma Z, Duan J, Zhang G, Huang T, Li Y, Wu H, Zhang T, Zhu A, Jin C, Song X, Su B |
Frontiers in Immunology | 2025 |
Intestinal Microbiota and Vaccinations: A Systematic Review of the Literature
Loddo F, Laganà P, Rizzo CE, Calderone SM, Romeo B, Venuto R, Maisano D, Fedele F, Squeri R, Nicita A, Nirta A, Genovese G, Bartucciotto L, Genovese C |
Vaccines | 2025 |
Hybrid Immunity from Gam-COVID-Vac Vaccination and Natural SARS-CoV-2 Infection Confers Broader Neutralizing Activity against Omicron Lineage VOCs Than Revaccination or Reinfection.
Kulemzin SV, Guselnikov SV, Nekrasov BG, Molodykh SV, Kuvshinova IN, Murasheva SV, Belovezhets TN, Gorchakov AA, Chikaev AN, Chikaev NA, Volkova OY, Yurina AA, Najakshin AM, Taranin AV |
Human vaccines | 2024 |
Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab
Ziemssen T, Groth M, Ettle B, Bopp T |
Human Vaccines & Immunotherapeutics | 2024 |
Serological assessment of the durability of vaccine-mediated protection against SARS-CoV-2 infection.
Bates JT, Lirette ST, Farmer AP, Bierdeman MA, Seyfarth KB, Ederer DR, Montgomery DD, Burnett GC, Pham AT, Marshall GD |
Human Vaccines & Immunotherapeutics | 2024 |
Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination.
Martín Pérez C, Aguilar R, Jiménez A, Salmerón G, Canyelles M, Rubio R, Vidal M, Cuamba I, Barrios D, Díaz N, Santano R, Serra P, Santamaria P, Izquierdo L, Trilla A, Vilella A, Barroso S, Tortajada M, García-Basteiro AL, Moncunill G, Dobaño C |
BMC Medicine | 2024 |
Effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine in Korea: interim analysis
Nham E, Sohn JW, Choi WS, Wie SH, Lee J, Lee JS, Jeong HW, Eom JS, Choi YJ, Seong H, Yoon JG, Noh JY, Song JY, Cheong HJ, Kim WJ |
Frontiers in immunology | 2024 |
COVID-19 Vaccination Strategies in the Endemic Period: Lessons from Influenza
Nham E, Noh JY, Park O, Choi WS, Song JY, Cheong HJ, Kim WJ |
Human vaccines | 2024 |
Appropriate Sampling and Longer Follow-Up Are Required to Rigorously Evaluate Longevity of Humoral Memory After Vaccination
Ganusov VV |
ImmunoHorizons | 2024 |
Genomic surveillance and vaccine response to the dominant SARS-CoV-2 XBB lineage in Rio Grande do Sul
Piccoli BC, y Castro TR, Tessele LF, Casarin BC, Seerig AP, Vieira AD, Santos VT, Schwarzbold AV, Trindade PA |
Scientific Reports | 2024 |
The contributions of T cell-mediated immunity to protection from vaccine-preventable diseases: A primer
Shapiro JR, Corrado M, Perry J, Watts TH, Bolotin S |
Human Vaccines & Immunotherapeutics | 2024 |
Germinal Center Response to mRNA Vaccination and Impact of Immunological Imprinting on Subsequent Vaccination.
Kim W |
Immune network | 2024 |
Durability of immune responses to SARS-CoV-2 infection and vaccination
Suthar MS |
Seminars in immunology | 2024 |
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study
Essink BJ, Shapiro C, Isidro MG, Bradley P, Pragalos A, Bloch M, Santiaguel J, Frias MV, Miyakis S, Alves de Mesquita M, Berrè S, Servais C, Waugh N, Hoffmann C, Baba E, Schönborn-Kellenberger O, Wolz OO, Koch SD, Ganyani T, Boutet P, Mann P, Mueller SO, Ramanathan R, Gaudinski MR, Vanhoutte N |
Human Vaccines & Immunotherapeutics | 2024 |
Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant
Laghlali G, Wiest MJ, Karadag D, Warang P, O\u2019Konek JJ, Chang LA, Park SC, Yan V, Farazuddin M, Janczak KW, García-Sastre A, Baker JR Jr, Wong PT, Schotsaert M |
Molecular Therapy | 2024 |
T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly Subjects
Segato I, Mele D, Forlani G, Dalla Gasperina D, Mondelli MU, Varchetta S |
Vaccines | 2024 |
Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2
Livieratos A, Schiro LE, Gogos C, Akinosoglou K |
Vaccines | 2024 |
Multi-Antigen Elephant Endotheliotropic Herpesvirus (EEHV) mRNA Vaccine Induces Humoral and Cell-Mediated Responses in Mice
Watts JR, Clinton JL, Pollet J, Peng R, Tan J, Ling PD |
Vaccines | 2024 |
Transforming Vaccinology
Rappuoli R, Alter G, Pulendran B |
Cell | 2024 |
AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans
Grigoryan L, Feng Y, Bellusci L, Lai L, Wali B, Ellis M, Yuan M, Arunachalam PS, Hu M, Kowli S, Gupta S, Maysel-Auslender S, Maecker HT, Samaha H, Rouphael N, Wilson IA, Moreno AC, Suthar MS, Khurana S, Pillet S, Charland N, Ward BJ, Pulendran B |
Science immunology | 2024 |
Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen
Casmil IC, Bathula NV, Huang C, Wayne CJ, Cairns ES, Friesen JJ, Soriano SK, Liao S, Ho CH, Kong KY, Blakney AK |
Molecular Therapy | 2024 |
Neutralizing Activity and T-Cell Responses Against Wild Type SARS-CoV-2 Virus and Omicron BA.5 Variant After Ancestral SARS-CoV-2 Vaccine Booster Dose in PLWH Receiving ART Based on CD4 T-Cell Count
Ha NY, Kim AR, Jeong H, Cheon S, Park CR, Choe JH, Kim HJ, Yoon JW, Kim M, An MY, Jung S, Do HN, Lee J, Kim YS |
Journal of Korean Medical Science | 2024 |
Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
Akerman A, Milogiannakis V, Jean T, Esneau C, Silva MR, Ison T, Fichter C, Lopez JA, Chandra D, Naing Z, Caguicla J, Li D, Walker G, Amatayakul-Chantler S, Roth N, Manni S, Hauser T, Barnes T, Condylios A, Yeang M, Wong M, Foster CSP, Sato K, Lee S, Song Y, Mao L, Sigmund A, Phu A, Vande More AM, Hunt S, Douglas M, Caterson I, Britton W, Sandgren K, Bull R, Lloyd A, Triccas J, Tangye S, Bartlett NW, Darley D, Matthews G, Stark DJ, Petoumenos K, Rawlinson WD, Murrell B, Brilot F, Cunningham AL, Kelleher AD, Aggarwal A, Turville SG |
EBioMedicine | 2023 |
A comprehensive perspective on the interaction between gut microbiota and COVID-19 vaccines
Hong M, Lan T, Li Q, Li B, Yuan Y, Xu F, Wang W |
Gut microbes | 2023 |
Appropriate sampling and long follow-up are required to rigorously evaluate longevity of humoral memory after vaccination.
Ganusov VV |
||
Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study
Kanokudom S, Suntronwong N, Duangchinda T, Wanlapakorn N, Poovorawan Y |
Cureus | 2023 |
Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2
Jacobsen H, Sitaras I, Katzmarzyk M, Cobos Jiménez V, Naughton R, Higdon MM, Deloria Knoll M |
npj Vaccines | 2023 |
Appropriate sampling and long follow-up are required to rigorously evaluate longevity of humoral memory after Vaccination
Ganusov VV |
2023 | |
Dynamics of Serum-Neutralizing Antibody Responses in Vaccinees through Multiple Doses of the BNT162b2 Vaccine
Sheehan J, Ardizzone CM, Khanna M, Trauth AJ, Hagensee ME, Ramsay AJ |
Human vaccines | 2023 |
The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in China.
Jiang H, Jin P, Guo X, Zhu J, Wang X, Wan P, Wan J, Liu J, Li J, Zhu F |
Human vaccines | 2023 |
An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants
Liu Z, Li J, Pei S, Lu Y, Li C, Zhu J, Chen R, Wang D, Sun J, Chen K |
Frontiers in Cellular and Infection Microbiology | 2023 |
SARS-CoV-2 breakthrough infections following inactivated vaccine vaccination induce few neutralizing antibodies against the currently emerging Omicron XBB variants.
Shen F, Liang C, Yang CX, Lu Y, Li AQ, Duan Y, Zhang M, Tian RR, Dong XQ, Zheng YT, Pang W |
Virologica Sinica | 2023 |